There have been no open-market insider trades at Oncternal Therapeutics, Inc. in the last 12 months.
Zooming out by quarter: No open-market insider buying or selling in the last full quarter. Insiders bought in 0 of the last 7 full quarters.
Oncternal Therapeutics, Inc. (ONCT): insider trading, Congress trades & who owns it
Insider signal
40/100
Insider selling · 90 days
Insider buys
$0
0 buyers · 12 months
Insider sales
$0
0 sellers · 12 months
Funds holding
—
13F filings
Congress trades
None
none in 2 years
Want the full picture on ONCT? Price & valuation, financials by quarter, who owns it, dilution, earnings and a written bull & bear case. See what's inside ↓
See the full ONCT report — free accountLatest insider trades in ONCT
| Filed | Insider | Role | Type | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Apr 10, 2024 | Wills Robert James | Director | Buy | 3,086 | $8.96 | $28K | SEC |
| Apr 1, 2024 | Wills Robert James | Director | Buy | 6,914 | $8.48 | $59K | SEC |
| Feb 27, 2024 | HALE DAVID F | Director | Buy | 714 | $9.04 | $6K | SEC |
| Feb 27, 2024 | HALE DAVID F | Director | Buy | 266 | $9.04 | $2K | SEC |
| Feb 27, 2024 | Wills Robert James | Director | Sell | 980 | $9.04 | $9K | SEC |
| Jun 14, 2023 | Kaufmann Gunnar F. | Executive Officer | Buy | 3,000 | $0.36 | $1K | SEC |
| Jun 14, 2023 | Kaufmann Gunnar F. | Executive Officer | Buy | 25,000 | $0.35 | $9K | SEC |
| Apr 17, 2023 | BREITMEYER JAMES B | CEO | Buy | 100,000 | $0.29 | $29K | SEC |
| Apr 17, 2023 | BREITMEYER JAMES B | CEO | Buy | 2,250 | $0.29 | $652 | SEC |
| Apr 17, 2023 | BREITMEYER JAMES B | CEO | Buy | 47,750 | $0.30 | $14K | SEC |
| Apr 14, 2023 | Yazji Salim | Executive Officer | Buy | 5,000 | $0.30 | $2K | SEC |
| Apr 14, 2023 | Yazji Salim | Executive Officer | Buy | 10,000 | $0.29 | $3K | SEC |
| Apr 14, 2023 | Leavitt Chase C. | Executive Officer | Buy | 15,000 | $0.29 | $4K | SEC |
| Apr 14, 2023 | Leavitt Chase C. | Executive Officer | Buy | 10,000 | $0.29 | $3K | SEC |
| Apr 14, 2023 | VINCENT RICHARD G | CFO | Buy | 30,000 | $0.30 | $9K | SEC |
The full ONCT report
This page shows the insider trades. The full ONCT report shows everything around them.
Price and valuation, revenue and profit by quarter, who owns it, dilution, earnings timing and a written bull & bear case, in one report you can also print or save as a PDF. Here is what each section looks like (screenshots from a real report):
Live price & key numbersScout
Price, market cap, P/E, revenue and profit growth at a glance.
Bull case vs bear caseAnalyst
A written read of everything below: what supports the stock, what worries.
Insider signal scoreFree
A 0-100 score with the reasons, plus earnings date, volatility and analyst ratings (Analyst).
Revenue & profit by quarterScout
Three years of results from SEC filings, growth marked quarter by quarter.
Insider buying vs selling by quarterScout
Streaks like “7 quarters of net selling” spotted for you.
Who owns it (13F)Scout
Top funds, who added, who cut and who sold out last quarter.
Congress tradesFree
Every House and Senate trade in the stock, late filers flagged.
Dilution trackerAnalyst
Stock offerings, shelf registrations and share-count growth, scored.
Snapshot for your trading styleAnalyst
Day trading, swing trading and long-term numbers side by side.
Free plan: insider trades, insider signal and Congress trades. Sections marked Scout or Analyst unlock with that plan (from $29/month). Screenshots: Micron Technology report, Oct 19, 2026.
Questions about ONCT
Are insiders buying or selling ONCT stock?
There were no open-market insider trades in ONCT in the last 12 months. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
Has any member of Congress traded ONCT?
No congressional trades in ONCT were reported in the past two years. The full list is free on CapitalSnitch.
Also active in insider buying
Free weekly email: the week's biggest insider buys and Congress trades, every Monday. No spam, one-click unsubscribe.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1). Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).